FDA Removes 12 Peptides from Category 2: What It Means for BPC-157 & GHK-Cu
TL;DR
The FDA is removing 12 peptides, including BPC-157 and GHK-Cu, from its Category 2 list of bulk drug substances. This move, announced by Secretary Kennedy, aims to restore regulated access through compounding pharmacies and curb the dangerous black market. These peptides will now undergo rigorous scientific evaluation by the Pharmacy Compounding Advisory Committee (PCAC) starting in July.
The FDA's Shift on Peptide Regulations
In September 2023, the FDA placed numerous popular peptides into Category 2, labeling them as "Bulk Drug Substances that Raise Significant Safety Risks." This effectively halted compounding pharmacies from producing them, driving many consumers toward unregulated black markets. However, a recent announcement by Secretary Kennedy signals a major regulatory pivot.
Following the withdrawal of 12 peptides by nominators, the FDA is officially removing them from the restrictive Category 2 list. This long-overdue action is designed to restore science-backed accountability and provide clarity for patients and providers alike.
Which Peptides Are Affected?
The regulatory update impacts some of the most widely researched compounds in the longevity and wellness space. These peptides are often included in a comprehensive peptide stack for their potential supportive benefits.
The 12 peptides being removed from Category 2 include:
| Peptide | Primary Research Focus |
|---|---|
| BPC-157 | Tissue repair and gut health |
| Thymosin Beta-4 Fragment (LKKTETQ) | Immune modulation and tissue healing |
| Epitalon | Telomere support and longevity |
| GHK-Cu (injectable) | Skin elasticity and wound healing |
| MOTS-c | Metabolic function and energy |
| DSIP (Emideltide) | Sleep regulation and stress response |
| Dihexa Acetate | Cognitive function and neuroprotection |
| Ibutamoren Mesylate (MK-677) | Growth hormone secretion and muscle support |
| Melanotan II | Melanocyte stimulation and libido research |
| KPV | Anti-inflammatory and gut health support |
| Semax (Heptapeptide) | Neuroprotection and cognitive enhancement |
| Cathelicidin LL-37 | Antimicrobial and immune defense |
What This Means for Access and Safety
Removing these peptides from Category 2 does not mean they are fully FDA-approved drugs. Instead, it opens the door for regulated compounding while independent experts rigorously evaluate them. Beginning in July, the Pharmacy Compounding Advisory Committee (PCAC) will review each substance based on full clinical, pharmacological, and safety evidence.
By shifting demand away from the black market, this action helps ensure that individuals seeking peptide therapies can eventually access them through legitimate, regulated channels. As Secretary Kennedy noted, the goal is to follow the science and enforce the law while delivering clarity to the medical community.
Frequently Asked Questions
Are these 12 peptides fully FDA-approved now?
No. Removal from Category 2 means they are no longer banned from compounding due to "significant safety risks," but they still must undergo evaluation by the PCAC to determine their final regulatory status.
When will the PCAC review these peptides?
The FDA will bring these peptides to the Pharmacy Compounding Advisory Committee (PCAC ) at its next two meetings, beginning in July.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information provided on this website is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional.